Giripladib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Giripladib
Accession Number
DB15426
Description

Giripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 745.25
Monoisotopic: 744.203641
Chemical Formula
C41H36ClF3N2O4S
Synonyms
Not Available
External IDs
  • PLA-695

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
1W10Q5H7WD
CAS number
865200-20-0
InChI Key
NHHBNHIPCSPSHQ-UHFFFAOYSA-N
InChI
InChI=1S/C41H36ClF3N2O4S/c42-33-22-23-37-35(26-33)34(16-9-10-28-18-20-31(21-19-28)40(48)49)38(47(37)39(29-11-3-1-4-12-29)30-13-5-2-6-14-30)24-25-46-52(50,51)27-32-15-7-8-17-36(32)41(43,44)45/h1-8,11-15,17-23,26,39,46H,9-10,16,24-25,27H2,(H,48,49)
IUPAC Name
4-{3-[5-chloro-1-(diphenylmethyl)-2-(2-{[2-(trifluoromethyl)phenyl]methanesulfonamido}ethyl)-1H-indol-3-yl]propyl}benzoic acid
SMILES
OC(=O)C1=CC=C(CCCC2=C(CCNS(=O)(=O)CC3=C(C=CC=C3)C(F)(F)F)N(C(C3=CC=CC=C3)C3=CC=CC=C3)C3=C2C=C(Cl)C=C3)C=C1

References

General References
Not Available
ChemSpider
9896558
ChEMBL
CHEMBL2104969
ZINC
ZINC000085537113

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentOsteoarthritis (OA)1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentRheumatoid Arthritis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.49e-05 mg/mLALOGPS
logP7.35ALOGPS
logP10.22ChemAxon
logS-7.5ALOGPS
pKa (Strongest Acidic)4.24ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area88.4 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity198.91 m3·mol-1ChemAxon
Polarizability76.7 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 09:29 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates